

Supplementary Information for:

COVID-19 severity is associated with immunopathology and multi-organ damage

Yan-Mei Chen^{1,4}, Yuanting Zheng^{1,4}, Ying Yu^{1,4}, Yunzhi Wang^{1,4}, Qingxia Huang^{1,4}, Feng Qian^{1,4}, Lei Sun^{2,4}, Zhi-Gang Song¹, Ziyin Chen¹, Jinwen Feng¹, Yanpeng An¹, Jingcheng Yang¹, Zhenqiang Su¹, Shanyue Sun¹, Fahui Dai¹, Qinsheng Chen¹, Qinwei Lu¹, Pengcheng Li¹, Yun Ling¹, Zhong Yang¹, Huiru Tang¹, Leming Shi¹, Li Jin¹, Edward C. Holmes³, Chen Ding^{1*}, Tong-Yu Zhu^{1*}, Yong-Zhen Zhang^{1*}





¹Shanghai Public Health Clinical Center, State Key Laboratory of Genetic Engineering, School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China.

²Institute of Developmental Biology and Molecular Medicine, Fudan University, Shanghai, China.

³Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia.

⁴These authors contributed equally: Yan-Mei Chen, Yuanting Zheng, Ying Yu, Yunzhi Wang, Qingxia Huang, Feng Qian, Lei Sun

*Correspondence to: Yong-Zhen Zhang, Email: zhangyongzhen@shphc.org.cn; Tong-Yu Zhu, Email: zhutongyu@shphc.org.cn; Chen Ding, Email: chend@fudan.edu.cn.



25 **Fig. S1 Molecular variation associated with COVID-19 pathophysiology.**

26 (A) Scores of principal components 2 and 3 (PC2 and PC3) of each sample from the RNA-
27 seq, proteome, metabolome, and exRNA-seq principal component analyses.


28 (B) Systematic summary of the proteins and signaling cascades significantly altered in
29 healthy control patients (TCA, PEP) and in mild or severe patients (HIF-1 α). Values for each
30 protein in all samples analyzed (columns) are color-coded based on expression levels: low
31 (blue) and high (red) z-scored FOT.

32 (C) Network indicating protein-protein interactions among module 1 enriched proteins.


33 (D) Network indicating protein-protein interactions among module 2 enriched proteins.

34


A




Tissue specific proteins upregulated in severe patients




Tissue specific proteins upregulated in mild patients




B



C



36 **Fig. S2 Comparative analysis of tissue injury in mild and severe COVID-19 patients.**
37 (A and B) The heatmap indicates expression patterns of tissue-enhanced biomarkers among
38 the healthy control, mild and severe patient groups. A, tissue-enhanced proteins upregulated
39 in severe patients; B, tissue-enhanced proteins upregulated in mild patients. Values for each
40 protein in all samples analyzed (columns) are color-coded based on expression levels: low
41 (blue) and high (red) z-scored FOT. The bar plots indicate GO processes and pathways
42 enriched by tissue-specific proteins upregulated in mild patients (a) and severe patients (b).
43 (C) exRNA data related to tissue injury were collected from publications. Differentially
44 expressed exRNAs were identified using a t-test <0.05 and fold change >2 or <0.5 . The
45 majority of tissue-injury related exRNAs across all tissues analyzed showed differential
46 expression.
47



48

49 **Fig. S3 Immune characteristics in COVID-19 patients.**

50 (A) Normalized gene expression of innate immune signaling negative regulators in mild

51 versus severe COVID-19 patient comparisons.

52 (B) Level of plasma cytokines IL-8 between mild and severe patient groups.

53 (C) Absolute neutrophil count (NEUT) between mild and severe patient groups.

54 (D) Normalized expression of neutrophil activation genes in mild versus severe COVID-19
55 patient comparisons.

56 (E) Cell type enrichment analysis of the RNA sequencing data using the xCell tool among
57 COVID-19 patient subgroups from longitudinal samples.


58 (F) Expression levels of immune checkpoints, normalized to *CD3G* mild versus severe
59 patient comparisons.

60 (G) Expression levels of *ARG1* between control and COVID-19 patient subgroups.

61 (H) Comparison of TCR diversity between healthy controls and COVID-19 patient
62 subgroups. FC, fold change. Data are represented as means \pm SEM. ** $p < 0.01$; *** $p <$

63 0.001 (t-test).

64



65




66 **Fig. S4 COVID-19-caused changes in plasma metabolomics and clinical biochemistry**
 67 **associated with disease severity.**

68 (A-C) COVID-19 severity was associated with plasma metabolomic phenotypes defined by
 69 all MS-detectable lipidomic compounds (a), hydrophilic metabolites (b), and all NMR-
 70 detectable metabolite signals (c).

71 (D) PCA scores revealed a variation in plasma metabolomic trajectory among healthy
 72 controls, patients with mild and severe COVID-19, and upon discharge. The discharge group
 73 comprised all patients (mild and severe) that were recovered and discharged.

74 (E-H) COVID-19 severities are associated with changes in levels of the compositional
 75 components of lipoprotein subclasses (E and F), lactate (G), lactate dehydrogenase (H) in
 76 blood plasma. AU: The metabolite concentration of each sample is normalized using the

77 average of the control group; LDH: lactate dehydrogenase; H1: HDL1; H2: HDL2; H3: HDL3;
78 H4: HDL4; L: LDL; L2: LDL2; TG: triglycerides; FC: free cholesterol; CE: cholesteryl esters;
79 CH: total cholesterol (i.e., FC + CE); PL: total phospholipids; L5CE, L5FC, L5PL: cholesteryl
80 esters (CE), free cholesterol (FC) and total phospholipids (PL) in LDL5 (L5); ApoA2: total
81 ApoA2 (in both nascent and mature HDL); CH: total cholesterol (both FC and CE); H4A1,
82 H4A2, H4CH, H4FC, H4CE, H4PL: ApoA1, ApoA2, CH, FC, CE and PL in HDL4; LDPL,
83 LDL-CH, LDL-CE: PL, CH, CE in LDL; L-CE%, L-FC%: percentages of CE and FC in all
84 lipids of LDL. *** $p < 0.001$.
85



86




87 **Fig. S5 Training and validation set performance in exRNA-, transcriptome-, proteome-,**

88 **and clinical- models.**

89 (A) Workflow of prediction model construction.

90 (B) Performance of AI models in the training and validation set based on exRNA,
91 transcriptome, proteome, and the corresponding clinical covariate data sets. The model
92 performance of 5-fold cross-validation was assessed using Matthews correlation coefficient
93 (MCC), AUC, accuracy, sensitivity, specificity, positive predictive value (PPV) and negative
94 predictive value (NPV).

95 (C) Learning curve model comparison (LCMC) revealing sample size effects on the
96 accuracy and variability of the predictive models using cross-validation. Each individual root
97 means square error (RMSE) learning curve and the average for each of 8 models is shown.
98 The LCMC suggested that with up to 15 samples, 8 partition tree models reached AUC as 1
99 for clinical endpoints, but more than 23 samples were needed for one model and more than
100 30 samples need for three models to reach AUC as 1 for microRNA.
101



102

103

Fig. S6 A drug-protein network for predicting novel drug candidates.

104

(A) The snaky plot indicates the correlation network of drug, drug targets and predicted-

105

drug targets.

106 (B) Network indicating the interactions between Ribavirin, IMPDH1 (target of Ribavirin) and
107 predicted druggable proteins in mild COVID-19 patients.

108 (C) Network indicating the interactions between Sunitinib, KIT (target of Sunitinib) and
109 predicted druggable proteins in severe COVID-19 patients.